Literature DB >> 18439387

Household transmission of carbapenemase-producing Klebsiella pneumoniae.

Tamar Gottesman, Orly Agmon, Orna Shwartz, Michael Dan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18439387      PMCID: PMC2600260          DOI: 10.3201/eid1405.071340

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Since its first description in 2001, carbapenemase-producing Klebsiella pneumoniae has become a frequent nosocomial pathogen in the eastern United States (). This bacterium was introduced into Israel in 2005 and is endemic now in several hospitals in the country (). We recently documented transmission of this organism within a household, the source being a debilitated patient who returned home after a long hospitalization. A 73-year-old man had a urologic procedure (transurethral resection of the bladder neck) in a community hospital in early October 2007. He was initially evaluated on September 23, 2007, at an outpatient clinic where a routine urine sample was obtained for culture. Carbapenemase-producing K. pneumoniae was cultured. Identification and susceptibility testing of the isolate were completed by using the VITEK 2 system (bioMérieux, Marcy l’Etoile, France). K. pneumoniae carbapenemase was confirmed by using the modified Hodge test (). Two repeat urine cultures grew the same organism; however, a stool culture was negative for carbapenemase-producing K. pneumoniae. The medical history of the patient included hypertension and carcinoma of the prostate gland that was treated with high-intensity focused ultrasound in May 2007, followed by transurethral resection of prostate in June 2007. The 2 procedures were performed in 2 different private hospitals, and each required a 24-hour hospitalization. No carbapenemase-producing K. pneumoniae was documented in these hospitals. Two months before detection of carbapenemase-producing K. pneumoniae, the patient received a 1-week course of oral amoxicillin-clavulanate for presumed urinary tract infection, although urine culture obtained on July 29, 2007 was sterile. A repeat urine culture 2 weeks later (August 13, 2007) remained sterile. Because the circumstances of strain acquisition and patient characteristics were not typical for epidemiology of carbapenemase-producing K. pneumoniae (), he was further questioned about possible contacts of relevance. The patient disclosed that his wife, who had amyotrophic lateral sclerosis that required mechanical ventilation, had been hospitalized in a tertiary hospital in the Tel Aviv area for 9 weeks until July 19, 2007. After discharge, she has been staying at home where she was cared for by her son, sister, and nurses; the patient stated that he had limited contact with his wife (he did not participate in her care). The infection control unit of the tertiary hospital was contacted, and the name of the wife was identified in the hospital registry. Carbapenemase-producing K. pneumoniae was isolated from her urine on June 8, 2007. Despite limited contact, the patient probably acquired carbapenemase-producing K. pneumoniae from his wife, who was a documented carrier of this organism. Because his early urine cultures (taken after his wife was discharged from hospital) were sterile, we can assume that the transmission of the organism occurred at their home. We cannot rule out that the strain was transferred by an intermediary, such as the couple’s son. It is unlikely that the organism was acquired at the private hospitals from which no case of carbapenemase-producing K. pneumoniae was reported (in Israel reporting carbapenemase-producing K. pneumoniae isolates to health authorities is mandatory). Also, the patient had 2 negative urine cultures. Carbapenemase-producing K. pneumoniae is a recent addition to the pool of multidrug-resistant nosocomial pathogens. Most publications on this organism have focused on issues of structural and molecular epidemiology. Little is known regarding clinical characteristics and importance of infection with this organism. Until now, the strain has been recovered only from hospitalized patients with a longer hospital stay, those given multiple antimicrobial drug courses, and those mechanically ventilated (,). The strain can colonize the urinary, intestinal, and respiratory tracts, as well as wounds; bloodstream infection is associated with higher death rates than infection at other sites (). Hand carriage is probably the biggest factor in transmission of extended-spectrum β-lactamase producers, and there is little evidence to suggest that carriers of carbapenemase-producing K. pneumoniae would be different. Environmental contamination plays a limited role in transmission of the organism (). Caregivers should be aware that multidrug-resistant organisms of nosocomial origin can be transmitted in the community (). Acquisition of such strains is probably of negligible importance in an otherwise healthy person. However, consequences may be different if the recipient of the strain is a debilitated patient.
  3 in total

1.  Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004).

Authors:  Lalitagauri M Deshpande; Ronald N Jones; Thomas R Fritsche; Helio S Sader
Journal:  Microb Drug Resist       Date:  2006       Impact factor: 3.431

2.  Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.

Authors:  Esther Calbo; Verónica Romaní; Mariona Xercavins; Lucía Gómez; Carolina Garcia Vidal; Salvador Quintana; Jordi Vila; Javier Garau
Journal:  J Antimicrob Chemother       Date:  2006-02-21       Impact factor: 5.790

3.  Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.

Authors:  Azita Leavitt; Shiri Navon-Venezia; Inna Chmelnitsky; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

  3 in total
  5 in total

1.  Household Transmission of Carbapenemase-producing Enterobacterales in Ontario, Canada.

Authors:  Alainna J Jamal; Amna Faheem; Lubna Farooqi; Xi Zoe Zhong; Irene Armstrong; David A Boyd; Emily Borgundvaag; Brenda L Coleman; Karen Green; Kithsiri Jayasinghe; Jennie Johnstone; Kevin Katz; Philipp Kohler; Angel X Li; Laura Mataseje; Roberto Melano; Matthew P Muller; Michael R Mulvey; Sarah Nayani; Samir N Patel; Aimee Paterson; Susan Poutanen; Anu Rebbapragada; David Richardson; Alicia Sarabia; Shumona Shafinaz; Andrew E Simor; Barbara M Willey; Laura Wisely; Allison J McGeer
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

2.  Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system.

Authors:  Andrea Endimiani; John M Depasquale; Sandra Forero; Federico Perez; Andrea M Hujer; Daneshia Roberts-Pollack; Paul D Fiorella; Nancy Pickens; Brandon Kitchel; Aida E Casiano-Colón; Fred C Tenover; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2009-09-09       Impact factor: 5.790

3.  KPC-PRODUCING Serratia marcescens IN A HOME-CARE PATIENT FROM RECIFE, BRAZIL.

Authors:  Emmily Margate; Vera Magalhães; Lorena Cristina Corrêa Fehlberg; Ana Cristina Gales; Ana Catarina Souza Lopes
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Jul-Aug       Impact factor: 1.846

4.  Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control.

Authors:  A P Magiorakos; K Burns; J Rodríguez Baño; M Borg; G Daikos; U Dumpis; J C Lucet; M L Moro; E Tacconelli; G Skov Simonsen; E Szilágyi; A Voss; J T Weber
Journal:  Antimicrob Resist Infect Control       Date:  2017-11-15       Impact factor: 4.887

5.  Zooanthroponotic Transmission of Drug-Resistant Pseudomonas aeruginosa, Brazil.

Authors:  Miriam R Fernandes; Fábio P Sellera; Quézia Moura; Marcelo P N Carvalho; Paula N Rosato; Louise Cerdeira; Nilton Lincopan
Journal:  Emerg Infect Dis       Date:  2018-06       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.